CYTK Stock: Cytokinetics, Incorporated Stock Price, Analysis & Insights
Get live cytk stock price $61.56, comprehensive Cytokinetics, Incorporated stock analysis, charts, news, and expert forecast. Real-time cytk stock data and investment insights.
Loading chart...
Company Overview
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Company Information
- CEO
- Robert I. Blum
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 498
Contact Information
- Website
- https://www.cytokinetics.com
- Address
- 350 Oyster Point Boulevard
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.59) may provide portfolio stability
Business Model & Strategy
Cytokinetics, Incorporated operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Robert I. Blum, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Cytokinetics, Incorporated competes in the Biotechnology within the broader Healthcare. With 7.3 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Cytokinetics, Incorporated provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Cytokinetics, Incorporated should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Cytokinetics, Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Cytokinetics, Incorporated
- ⚠Investors should consider how Cytokinetics, Incorporated fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
7.32B
P/E Ratio
-9.77
Beta
0.59
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 7.32B market capitalization
- Trading Volume: 54.89K shares traded today
- Price Range: 52-week range of $29.31 - $69.33
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 7.32B, the company represents a significant player in its market. The stock is currently trading at $61.56 with a negativedaily change of 0.73%.
The company's 498 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -9.77, beta of 0.59, and 52-week price range from $29.31 to $69.33when evaluating investment opportunities.
Why Invest in Cytokinetics, Incorporated?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Robert I. Blum
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.